Primary relevance to vitamin D Vitamin D is a stated subject of this paper.
Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.
Why this paper is included
Supporting source evidence:
Serum levels of the active VitD metabolite 1,25(OH)2D3 were also significantly increased in VitD(+) participants compared with baseline (x̄ = 46.5 pg/mL, SEM = 1.5) and VitD(: ) participants at all matched time points (P < 0.001 for all; 24-hour VitD x̄ = 79.8 pg/mL, SEM = 4.8; 7-day x̄ = 72.2 pg/mL, SEM = 3.6).
Source: Safety and tolerability.. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Double-blind reported · Human research reported
Reported blinded roles: investigators.
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
This 8-week, randomized, double-blinded, placebo-controlled interventional trial included 28 healthy participants and occurred on a rolling basis between September 2017 and August 2018 ().
Source: Methods.
Participants were given PRO-Diary wrist-worn devices, which prompted them to record participative skin irritation, pain, and itching twice daily during both phases of the study.
Source: Methods.
Participants and investigators performing assessments were blinded to intervention assignments.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Vitamin D3 and deconvoluting a rash
Study design awaiting verification · JCI Insight · 2023
Original publication title
Vitamin D3 and deconvoluting a rash
© 2023 Ernst et al.
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What background does the paper provide?
Adverse drug reactions are unpredictable immunologic events presenting frequent challenges to clinical management. Systemically administered cholecalciferol (vitamin D3) has immunomodulatory properties. In this randomized, double-blinded, placebo-controlled interventional trial of healthy human adults, we investigated the clinical and molecular immunomodulatory effects of a single high dose of oral vitamin D3 on an experimentally induced chemical rash.
Source: BACKGROUNDAbstract: What methods does the paper describe?
Skin inflammation was induced with topical nitrogen mustard (NM) in 28 participants. Participant-specific inflammatory responses to NM alone were characterized using clinical measures, serum studies, and skin tissue analysis over the next week. All participants underwent repeat NM exposure to the opposite arm and then received placebo or 200,000 IU cholecalciferol intervention. The complete rash reaction was followed by multi-omic analysis, clinical measures, and serum studies over 6 weeks.
Source: METHODSAbstract: RESULTS
Cholecalciferol mitigated acute inflammation in all participants and achieved 6 weeks of durable responses. Integrative analysis of skin and blood identified an unexpected divergence in response severity to NM, corroborated by systemic neutrophilia and significant histopathologic and clinical differences. Multi-omic and pathway analyses revealed a 3-biomarker signature (CCL20, CCL2, CXCL8) unique to exaggerated responders that is suppressed by cholecalciferol and implicates IL-17 signaling involvement.
Source: RESULTSAbstract: CONCLUSION
High-dose systemic cholecalciferol may be an effective treatment for severe reactions to topical chemotherapy. Our findings have broad implications for cholecalciferol as an antiinflammatory intervention against the development of exaggerated immune responses.
Source: CONCLUSIONAuthors’ abstract
BACKGROUND
Adverse drug reactions are unpredictable immunologic events presenting frequent challenges to clinical management. Systemically administered cholecalciferol (vitamin D3) has immunomodulatory properties. In this randomized, double-blinded, placebo-controlled interventional trial of healthy human adults, we investigated the clinical and molecular immunomodulatory effects of a single high dose of oral vitamin D3 on an experimentally induced chemical rash.
METHODS
Skin inflammation was induced with topical nitrogen mustard (NM) in 28 participants. Participant-specific inflammatory responses to NM alone were characterized using clinical measures, serum studies, and skin tissue analysis over the next week. All participants underwent repeat NM exposure to the opposite arm and then received placebo or 200,000 IU cholecalciferol intervention. The complete rash reaction was followed by multi-omic analysis, clinical measures, and serum studies over 6 weeks.
RESULTS
Cholecalciferol mitigated acute inflammation in all participants and achieved 6 weeks of durable responses. Integrative analysis of skin and blood identified an unexpected divergence in response severity to NM, corroborated by systemic neutrophilia and significant histopathologic and clinical differences. Multi-omic and pathway analyses revealed a 3-biomarker signature (CCL20, CCL2, CXCL8) unique to exaggerated responders that is suppressed by cholecalciferol and implicates IL-17 signaling involvement.
CONCLUSION
High-dose systemic cholecalciferol may be an effective treatment for severe reactions to topical chemotherapy. Our findings have broad implications for cholecalciferol as an antiinflammatory intervention against the development of exaggerated immune responses.
TRIAL REGISTRATION
clinicaltrials.gov (NCT02968446).
FUNDING
NIH and National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS; grants U01AR064144, U01AR071168, P30 AR075049, U54 AR079795, and P30 AR039750 (CWRU)).
Publication and source details
Original title: Vitamin D3 and deconvoluting a rash
Madison K. Ernst; Spencer T. Evans; Jose-Marc Techner; Robert M. Rothbaum; Luisa F. Christensen; Ummiye Venus Onay; Dauren Biyashev; Michael M. Demczuk; Cuong V. Nguyen; Kord S. Honda; Thomas S. McCormick; Lam C. Tsoi; Johann E. Gudjonsson; Kevin D. Cooper; Kurt Q. Lu
JCI Insight · 2023
Address correspondence to: Kurt Lu, Northwestern University Feinberg SOM, 303 E. Chicago Ave. Ward 4-212, Chicago, Illinois 60611, USA. Phone: 312.503.2888; Email: Kurt.lu@northwestern.edu.Authorship note: MKE and STE are co: first authors.
Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T01:07:47.539501+00:00
DOI: 10.1172/jci.insight.163789 · PMC9977299